Critical parameters for particle-based pulmonary delivery of chemotherapeutics

• Main Authors: Abdul Rahman, N. (Author), Abu Kasim, N.H (Author), Dabbagh, A. (Author), Wong, T.W (Author), Yeong, C.H (Author)
• Format: Article
• Language: English
• Published: Mary Ann Liebert Inc. 2018
• Subjects: aerosol; Aerosols; antineoplastic agent; azacitidine; camptothecin; cancer chemotherapy; cancer classification; cancer staging; carboplatin; chemical composition; Chemotherapeutics; cisplatin; Clearance; clinical outcome; docetaxel; doxorubicin; drug carrier; Drug Carriers; drug delivery system; Drug Delivery Systems; dry powder inhaler; Dry Powder Inhalers; etoposide; fluorouracil; gelatin; gemcitabine; glucose; human; Humans; ifosfamide; lactose; ligand; ligand binding; lung; Lung; lung cancer; lung metastasis; Lung Neoplasms; lung tumor; mannitol; metabolism; mitomycin; nanocarrier; nanoparticle; non small cell lung cancer; nonhuman; osteosarcoma; oxaliplatin; paclitaxel; particle based pulmonary delivery system; particle size; Particle Size; Particles; pemetrexed; pharmacological parameters; physical chemistry; polymer; Pulmonary drug delivery systems; Review; small cell lung cancer; solid lipid nanoparticle; sorbitol; surface property; unindexed drug; vinblastine; vindesine; vinorelbine tartrate; xylitol
• Online Access: View Fulltext in Publisher; View in Scopus

 Targeted delivery of chemotherapeutics through the respiratory system is a potential approach to improve drug accumulation in the lung tumor, while decreasing their negative side effects. However, elimination by the pulmonary clearance mechanisms, including the mucociliary transport system, and ingestion by the alveolar macrophages, rapid absorption into the blood, enzymatic degradation, and low control over the deposition rate and location remain the main complications for achieving an effective pulmonary drug delivery. Therefore, particle-based delivery systems have emerged to minimize pulmonary clearance mechanisms, enhance drug therapeutic efficacy, and control the release behavior. A successful implementation of a particle-based delivery system requires understanding the influential parameters in terms of drug carrier, inhalation technology, and health status of the patient's respiratory system. This review aims at investigating the parameters that significantly drive the clinical outcomes of various particle-based pulmonary delivery systems. This should aid clinicians in appropriate selection of a delivery system according to their clinical setting. It will also guide researchers in addressing the remaining challenges that need to be overcome to enhance the efficiency of current pulmonary delivery systems for aerosols. © Copyright 2018, Mary Ann Liebert, Inc. 2018.